230 Studies Now Enrolling
Menu
Search
Status
Medical Condition
- Show all (57)
- Allergy, Asthma, & Immunology (1)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (5)
- Bone & Muscle (1)
- Cancer (9)
- COVID-19 (Coronavirus) (2)
- Diabetes (1)
- Gastrointestinal and Digestive Diseases (1)
- Hair and Skin Disorders (3)
- Healthy Volunteers (11)
- Heart Disease (3)
- Infectious Disease (1)
- Kidney Disease (1)
- Lung Disease (5)
- (-) Neurological Disorders (3)
- Obstetrics & Gynecology (2)
- Pediatrics (3)
- Psychiatric Disorders (1)
- Rehabilitation (1)
- Transplant (1)
- Vascular Conditions (1)
Displaying 1 - 4 of 4
Condition: Neurological Disorders / Brain Tumors
Investigator: Stergios Zacharoulis, MD
Status: Closed
Children and young adults with diffuse midline glioma will be treated with Focused Ultrasound (FUS) with DEFINITY microbubbles and neuro-navigator-controlled sonication. The overall goal of this study is to see if the study treatment plan will improve the outcome of participants with diffuse midline glioma, for which no known cure exists, and determine…
Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system…
Condition: Neurological Disorders
Investigator: Cheryl Waters, MD
Status: Closed
The purpose of this study is to test the effectiveness of investigational drug APL-130277 for patients with Parkinson's disease. APL-130277 is an investigational drug, which means that the study drug is currently being tested. It is not approved by the U.S. Food and Drug Administration (FDA). The active ingredient in APL-130277 is apomorphine, a medication…
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to see how effective two doses of an investigational new drug called IgPro20 is when given subcutaneously (a shot given into the fat layer between the skin and the muscle) to treat CIDP in patients that still require IVIG and also to look at how safe the IgPro20 is for patients.